<DOC>
	<DOCNO>NCT01018836</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high energy x-ray kill tumor cell . Drugs , riluzole , may make tumor cell sensitive radiation therapy . Giving riluzole together whole-brain radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose riluzole give together whole-brain radiation therapy treat patient brain metastasis .</brief_summary>
	<brief_title>Riluzole Whole-Brain Radiation Therapy Treating Patients With Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose riluzole administer concurrently standard whole-brain radiotherapy ( WBRT ) patient multiple brain metastasis . Secondary - To determine long-term toxicity riluzole administer WBRT . - To assess neurocognitive function treatment riluzole WBRT . - To determine MRI response brain metastasis treatment riluzole WBRT . - To compare survival patient treat riluzole WBRT publish historical data patient brain metastasis . - To evaluate response brain metastasis riluzole WBRT function expression glutamate receptor primary tumor specimen . OUTLINE : This dose-escalation study riluzole . Patients receive oral riluzole twice daily begin day 0 . Beginning within 2 day initiation riluzole , patient undergo whole-brain radiotherapy 15 fraction . Patients undergo neurocognitive quality-of-life assessment baseline , 5 week , 3 month . Tumor tissue sample collect laboratory biomarker study . After completion study treatment , patient follow 6 week , every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor Has ≥ 2 brain metastasis demonstrate baseline MRI Patients 1 metastasis eligible provide metastasis large radiosurgery amenable surgical resection Not consider surgical resection Eligible undergo wholebrain radiotherapy ( WBRT ) PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,000/μL Platelet count ≥ 50,000/μL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST/ALT ≤ 1.5 time ULN INR ≤ 1.5 time ULN Sodium normal Thyroidstimulating hormone normal Negative pregnancy test Fertile patient must use effective contraception , , ≥ 6 month completion study treatment No headache , disequilibrium , vertigo , dizziness No known history hepatitis B C No concurrent serious systemic disorder ( include active infection ) would compromise safety patient compromise patient 's ability complete study , discretion investigator No history allergic reaction attribute riluzole PRIOR CONCURRENT THERAPY : No prior WBRT At least 2 week since prior systemic chemotherapy No systemic chemotherapy ≥ 3 week completion WBRT Radiosurgical boost ≤ 3 metastasis allow , base discretion treat radiation oncologist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>tumor metastatic brain</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>